Beaufort Securities Reaffirms a “Buy” Rating on Hutchison China Meditech Ltd (LON:HCM); Inca Investments Trimmed Itau Unibanco Hdg Sa (ITUB) Holding By $4.69 Million

Inca Investments Llc decreased Itau Unibanco Hdg Sa (ITUB) stake by 8.16% reported in 2017Q3 SEC filing. Inca Investments Llc sold 361,000 shares as Itau Unibanco Hdg Sa (ITUB)’s stock declined 15.42%. The Inca Investments Llc holds 4.06 million shares with $55.65 million value, down from 4.42 million last quarter. Itau Unibanco Hdg Sa now has $97.96 billion valuation. The stock increased 0.13% or $0.02 during the last trading session, reaching $15.65. About 5.02M shares traded. Itaú Unibanco Holding S.A. (NYSE:ITUB) has risen 47.22% since February 14, 2017 and is uptrending. It has outperformed by 30.52% the S&P500.

Beaufort Securities reaffirmed their “Buy” rating on Hutchison China Meditech Ltd (LON:HCM)‘s stock in analysts report revealed on 14 February.

Among 8 analysts covering Itau Unibanco Banco Holding SA (NYSE:ITUB), 3 have Buy rating, 2 Sell and 3 Hold. Therefore 38% are positive. Itau Unibanco Banco Holding SA had 13 analyst reports since July 29, 2015 according to SRatingsIntel. The company was downgraded on Friday, April 8 by Citigroup. As per Wednesday, July 20, the company rating was upgraded by Goldman Sachs. The firm has “Sell” rating by Goldman Sachs given on Tuesday, March 29. The firm has “Underperform” rating given on Tuesday, October 13 by Credit Suisse. The rating was maintained by JP Morgan on Tuesday, August 16 with “Overweight”. The firm has “Overweight” rating given on Wednesday, April 27 by Barclays Capital. The company was downgraded on Tuesday, March 22 by Deutsche Bank. On Thursday, October 15 the stock rating was downgraded by Citigroup to “Neutral”. The company was upgraded on Wednesday, April 12 by Scotia Capital. As per Tuesday, March 15, the company rating was initiated by Scotia Capital.

Among 2 analysts covering Hutchison China Meditech Ltd (LON:HCM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Hutchison China Meditech Ltd has GBX 3840 highest and GBX 1750 lowest target. GBX 3840’s average target is -14.86% below currents GBX 4510 stock price. Hutchison China Meditech Ltd had 33 analyst reports since July 28, 2015 according to SRatingsIntel. As per Monday, December 21, the company rating was maintained by Beaufort Securities. The firm has “Buy” rating given on Monday, October 31 by Panmure Gordon. The rating was maintained by Beaufort Securities on Wednesday, March 2 with “Buy”. On Tuesday, January 10 the stock rating was maintained by Panmure Gordon with “Buy”. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Beaufort Securities on Tuesday, June 21. Beaufort Securities maintained Hutchison China MediTech Limited (LON:HCM) on Tuesday, March 22 with “Buy” rating. The firm has “Buy” rating by Beaufort Securities given on Wednesday, August 3. On Monday, January 18 the stock rating was maintained by Beaufort Securities with “Buy”. The firm has “Buy” rating by Panmure Gordon given on Thursday, May 18. The stock of Hutchison China MediTech Limited (LON:HCM) has “Buy” rating given on Monday, May 16 by Beaufort Securities.

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. The company has market cap of 2.99 billion GBP. It operates through Innovation Platform and Commercial Platform divisions. It has a 212.74 P/E ratio. The firm provides drug research and development services; and develops, makes, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands.